BASECLICK GMBH

Their core work

baseclick is a German biotech company specializing in click chemistry — a set of highly efficient chemical reactions used to modify and functionalize nucleic acids (DNA/RNA). They provide click chemistry reagents and services for applications ranging from gene therapy and gene editing to DNA nanotechnology and live cell imaging. Their core value lies in enabling researchers and pharma companies to label, modify, and engineer nucleic acids with precision, serving as a specialist supplier and research partner in EU training networks focused on next-generation genetic medicines and DNA-based materials.

What they specialise in

How they've shifted over time

In the early period (2015–2018), baseclick focused on foundational click chemistry for gene therapy (ClickGene) and DNA structural applications like origami and self-assembly (DNA-Robotics). From 2018 onward, their involvement shifted toward more applied and therapeutically oriented topics — photophysics of nucleic acids, CRISPR-based gene editing, immunotherapy, and epigenetic modification. The trajectory shows a clear move from chemical toolmaking toward direct involvement in next-generation genetic medicine and advanced nucleic acid therapeutics.

baseclick is migrating from a pure chemistry-tools provider toward the therapeutic application of nucleic acid modification, positioning themselves at the intersection of click chemistry and genetic medicine.

How they like to work

baseclick has never coordinated an H2020 project — they consistently join as a participant or third party in large MSCA training networks (all four projects are MSCA-ITN). With 41 unique consortium partners across 13 countries, they function as a specialist industry contributor embedded in broad academic consortia. This pattern suggests they are valued for providing specific reagents, know-how, or training placements rather than driving project design, making them a low-friction partner for consortia needing click chemistry expertise.

Through four MSCA training networks, baseclick has collaborated with 41 distinct partners across 13 countries, giving them a broad European academic network concentrated in the nucleic acid and chemical biology research community.

What sets them apart

baseclick occupies a rare niche as a private company whose entire business model revolves around click chemistry applied to nucleic acids — a field where most players are academic labs. Their consistent participation in MSCA training networks means they have deep connections to the next generation of researchers being trained in DNA nanotechnology, gene editing, and nucleic acid therapeutics. For any consortium needing an industry partner with hands-on click chemistry capability for nucleic acid applications, baseclick is one of very few commercial options in Europe.

Highlights from their portfolio

• NATURE-ETN
  Their most recent and highest-funded project (EUR 252,788), bridging click chemistry into the high-impact domains of CRISPR, immunotherapy, and epigenetics.
• DNA-Robotics
  Explores DNA-based nanorobotics and self-assembly — an unusual topic for a private company, showing baseclick's reach beyond conventional pharma applications.
• ClickGene
  Their first H2020 project and the one most directly aligned with their commercial identity: applying click chemistry to gene therapies for societal benefit.